Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am College Cardiol. 2018;71(19):e127-e248.

Article  PubMed  Google Scholar 

Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105.

Article  PubMed  Google Scholar 

Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-31.

Article  CAS  PubMed  Google Scholar 

Virani SS, Alonso A, Aparicio JH, et al. Heart Disease and Stroke Statistics—2021 Update. Circulation. 2021;143(8):E254-E743.

Article  PubMed  Google Scholar 

Grassi G. The Sympathetic Nervous System in Hypertension: Roadmap Update of a Long Journey. Am J Hyper. 2021;34(12):1247-54.

Article  PubMed  PubMed Central  Google Scholar 

Venkataraman S, Vungarala S, Covassin N, Somers VK. Sleep Apnea, Hypertension and the Sympathetic Nervous System in the Adult Population. J Clin Med. 2020;9(2):591.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai A, Calhoun DA. Resistant Hypertension: An update of experimental and clinical findings. Hypertension. 2017;70(1):5-9.

Article  CAS  PubMed  Google Scholar 

Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976-90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Grassi G, Bombelli M, Buzzi S, Volpe M, Brambilla G. Neuroadrenergic disarray in pseudo-resistant and resistant hypertension. Hyper Res. 2014;37(6):479-83.

Article  CAS  PubMed  Google Scholar 

Grassi G, Dell’Oro R, Quarti-Trevano F, Vanoli J, Oparil S. Sympathetic Neural Mechanisms in Hypertension: Recent Insights. Curr Hyper Rep. 2023;25(10):263-70.

Article  Google Scholar 

Dell’Oro R, Quarti-Trevano F, Seravalle G, et al. Sympathetic nerve traffic and arterial baroreflex function in apparent drug-resistant hypertension. Hypertension. 2019;74(4):903-9.

Article  PubMed  Google Scholar 

Ahmed M, Nudy M, Bussa R, Filippone EJ, Foy AJ. A systematic review and meta-analysis of all sham and placebo controlled trials for resistant hypertension. Eur J Intern Med. 2023;113:83-90.

Article  CAS  PubMed  Google Scholar 

Biffi A, Dell’Oro R, Quarti-Trevano F, et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension. 2023;80(3):659-67.

Article  CAS  PubMed  Google Scholar 

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124(7):1061-70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lohmeier TE, Hall JE. Device-Based Neuromodulation for Resistant Hypertension Therapy. Circ Res. 2019;124(7):1071-93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahfoud F, Schlaich MP, Lobo MD. Device Therapy of Hypertension. Circ Res. 2021;128(7):1080-99.

Article  CAS  PubMed  Google Scholar 

Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765-73.

Article  PubMed  Google Scholar 

Wallbach M, Born E, Kampfer D, et al. Long-term effects of baroreflex activation therapy: 2-year follow-up data of the BAT Neo system. Clin Res Cardiol. 2020;109(4):513-22.

Article  CAS  PubMed  Google Scholar 

Tolu-Akinnawo O, Ray DN, Awosanya T, Nzerue C, Okafor H. Hypertension and Device-Based Therapies for Resistant Hypertension: An Up-to-Date Review. Cureus. 2024;2024-08-06.

Ardhanari S, Kannuswamy R, Chaudhary K, Lockette W, Whaley-Connell A. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension. Adv Chronic Kidney Dis. 2015;22(3):185-95.

Article  PubMed  Google Scholar 

Brown JM, Siddiqui M, Calhoun DA, et al. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study. Ann Intern Med. 2020;173(1):10-20.

Article  PubMed  PubMed Central  Google Scholar 

Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059-68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim SK, Mccurley AT, Dupont JJ, et al. Smooth muscle cell–mineralocorticoid receptor as a mediator of cardiovascular stiffness with aging. Hypertension. 2018;71(4):609-21.

Article  CAS  PubMed  Google Scholar 

Galmiche G, Pizard A, Gueret A, et al. Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension. 2014;63(3):520-6

Article  CAS  PubMed  Google Scholar 

Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi SA, Jaffe IZ. Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol. 2014;34(2):355-64.

Article  CAS  PubMed  Google Scholar 

Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol. 2008;86(8):485-98.

Article  CAS  PubMed  Google Scholar 

Kostov K. The causal relationship between endothelin-1 and hypertension: focusing on endothelial dysfunction, arterial stiffness, vascular remodeling, and blood pressure regulation. Life. 2021;11(9):986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu M, Lu Y-P, Hasan A, Ahmed, Hocher B. Plasma ET-1 Concentrations are elevated in patients with hypertension – meta-analysis of clinical studies. Kidney Blood Press Res. 2017;42(2):304-13.

Heidari Nejad S, Azzam O, Schlaich MP. Dual endothelin antagonism with aprocitentan as a novel therapeutic approach for resistant hypertension. Current Hypertension Reports. 2023;25(10):343-52.

Article  Google Scholar 

Barbaro NR, De Araújo TM, Tanus-Santos JE, Anhê GF, Fontana V, Moreno H. Vascular damage in resistant hypertension: TNF-Alpha inhibition effects on endothelial cells. BioMed Res Int. 2015;2015:1-8.

Article  Google Scholar 

Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double‐blind, placebo‐controlled dose‐ranging study. J Clin Hyper. 2007;9(10):760-9.

Article  CAS  Google Scholar 

Danaietash P, Verweij P, Wang JG, et al. Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan. J Clin Hyper. 2022;24(7):804-13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benson LN, Guo Y, Deck K, Mora C, Liu Y, Mu S. The link between immunity and hypertension in the kidney and heart. Front Cardiovasc Med. 2023;10:1129384.

Article  CAS  PubMed  PubMed Central